Absstract of: WO2023001894A1

Provided are compositions containing extracellular vesicles from microalgae (MEVs) that are exogenously loaded with bioactive cargo or other cargo of interest, such as for therapeutic, industrial, diagnostic, and cosmetic uses. The MEVs have a variety of applications as therapeutics, including as vaccines, as anti-cancer therapeutics, as diagnostics, and other such uses.

Absstract of: WO2023002223A1

A nucleic acid vector composition comprising: one or more enzymes and/or one or more fragments thereof; a nucleic acid; one or more particles comprising hydrolysable silicon; and one or more lipids. Also related products, medical uses, and methods.

Absstract of: US2023026381A1

The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

Absstract of: US2023027864A1

The disclosure features immune cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to immune cells, in particular T cells, as well as B cells, dendritic cells and monocytes. The LNPs comprise an effective amount of an immune cell delivery potentiating lipid such that delivery of an agent by an immune cell delivery LNP is enhanced as compared to an LNP lacking the immune cell delivery potentiating agent. Methods of using the immune cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, for modulating immune cell activity and modulating immune responses are also disclosed.

Absstract of: US2023027885A1

Disclosed herein are methods and agents for the treatment of cancer using p53-independent apoptosis to reduce the number of p53-depleted or p53-mutated cancer cells that have amplified HER2 gene. Also disclosed herein are methods and agents for the treatment of HJ-R2-positive: cancer in individuals with Li-Fraumeni Syndrome.

Absstract of: US2023029277A1

The present invention relates generally to compositions and methods comprising abiotic, synthetic polymers with affinity and specificity to proteins. The synthetic polymers are an improvement over biological agents by providing a simpler, less expensive, and customizable platform for binding to proteins. In one embodiment, the compositions and methods relate to synthetic polymers with affinity and specificity to vascular endothelial growth factor (VEGF). In one embodiment, the compositions are useful for treating diseases and disorders related to the overexpression of VEGF. In one embodiment, the compositions are useful for treating cancer. In one embodiment, the compositions are useful for detecting VEGF levels from biological samples. In one embodiment, the compositions are useful for detecting overexpression of VEGF from biological samples. In one embodiment, the compositions are used to diagnose cancer.

Absstract of: US2023023368A1

Radiosensitizer prodrugs and formulations and methods of use thereof are provided. Typically, the radiosensitizer prodrug is an analog of a radiosensitizer parent compound having one or more S-nitrosothiol moieties. Typically, the S—N bond of the S-nitrosothiol moiety can be cleaved by radiation during radiotherapy, releasing the parent compound and nitric oxide. One or preferably both the parent compound and the nitric oxide can contribute to death of tumor cells exposed to radiotherapy. Nanoparticle formulations for delivery of the prodrug, and methods of using them in combination with radiotherapy to treat tumors and cancer are also provided.

Absstract of: US2023023342A1

A medicinal chewing gum has an inner core containing a first gum base and a first cannabinoid in a lipophilic nanosized form and an outer layer containing a second gum base and a second cannabinoid in a hydrophilic nanosized form, thereby providing quick release of the second cannabinoid in the outer layer and sustained release of the first cannabinoid in the inner layer. At least one of the inner core and the outer layer contains a synergistic compound having a synergistic effect with at least one of the first and second cannabinoids in the treatment of a medical condition.

Absstract of: US2023024537A1

Certain embodiments are directed to compositions and related methods for oral delivery of compositions for effective administration of leptin pathway modulating agents (e.g., leptin, anti-leptin antibodies, anti-leptin receptor antibodies and the like), the composition including an ionic liquid (e.g., CAGE) or a beta-glucan composition and a leptin pathway modulator for reducing or maintaining body weight. In certain aspects the leptin pathway modulator is leptin or an anti-leptin antibody. An ionic liquid (IL) is a salt in the liquid state.

Absstract of: US2023024928A1

The present disclosure relates to nanoemulsions of 5-amino-[4-(4-chlorobenzoyl)-3, 5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide (carboxy-amido-triazole or CAI), methods of preparing thereof, and their use in the treatment of inflammatory optic neuropathies.

Absstract of: WO2023002222A1

A pharmaceutical composition comprising particles comprising hydrolysable doped silicon and one or more lipids complexed with an active pharmaceutical ingredient, wherein the particles are doped at a level of at least 1 x1016 dopant atoms per cm3. Also related products, methods, and medical uses.

Absstract of: WO2023002224A1

A method of preparing an injectable or oral storage stable formulation, comprising: contacting a biological species with a delivery system comprising biocompatible solid particles to form a complex; then optionally, lyophilising the complex to form a powder; and then dispersing the complex in a biodegradable gel material to form the formulation, comprising the complex embedded in the biodegradable gel material. Also related products, methods, and medical uses.

Absstract of: WO2023001488A1

The present invention relates to a novel thermoreversible sol-gel composition for stability enhancement and ready-to-use liquid application of nanoparticulate systems, a pharmaceutical composition, comprising said thermoreversible sol-gel composition, as well as an in-situ method of producing said thermoreversible sol-gel composition, wherein the nanoparticulate system comprises a biological polymer and/or a synthetic polymer. Furthermore, the present invention also relates to said thermoreversible sol-gel composition for use in medicine and specifically for use in treating ulcerative colitis.

Absstract of: WO2023000350A1

Glycerol phenylbutyrate granules, comprising the following components in percentage by mass: 5%-15% of glycerol phenylbutyrate, 5%-45% of a solid carrier, 40%-80% of a filler, 1%-5% of an adhesive, 0.5%-3% of a disintegrating agent, 0.1%-1% of a lubricant, and 0.01%-0.5% of a flavoring agent. The present invention further provides a preparation method for the glycerol phenylbutyrate granules and an application of the glycerol phenylbutyrate granules in the preparation of a drug for treating an urea cycle disorder. By screening the type and proportion of the solid carrier and a combination mode of the solid carrier and the glycerol phenylbutyrate, the glycerol phenylbutyrate can be uniformly adsorbed onto the solid carrier, and then granulated together with conventional adjuvants to obtain the granules. The granules have the characteristics of being convenient in carrying, good in stability, high in compliance, capable of mitigating stomach discomfort, etc.

Absstract of: WO2023004387A1

In one aspect, the disclosure relates to nanoclusters comprising cores comprising self-assembled unimolecular nanoparticles and biomimetic membrane coatings surrounding the cores, methods of making the same, and methods of treating and preventing restenosis using same. In some embodiments, the nanoclusters can contain an anti-restenotic drug. In one embodiment, the polymers and/or copolymers of the unimolecular nanoparticles can contain a hydrophobic group such as, for example, a phenylboronic ester. In a further embodiment, the biomimetic membrane can localize the nanoclusters at sites of vascular damage, at which time reactive oxygen species (ROS) at the sites of vascular damage cleave the hydrophobic groups from the polymers and/or copolymers, increasing hydrophilicity of the polymers and/or copolymers and allowing for greater tissue penetration of the de-clustered nanoclusters and nanoparticles.

Absstract of: WO2023004437A1

The present invention features method and composition that can be used to facilitate intracellular delivery of DNA to a subject. The provided methods and compositions employ a nanoparticle for intracellular DNA delivery and a cytosolic DNA-sensing inhibitor. The cytosolic DNA-sensing inhibitor is provided to decrease the subject's immune response that can be stimulated by the DNA.

Absstract of: WO2023004002A1

An aspect of the present invention provides tissue-selective delivery of thyroid hormone receptor (TR)β agonists or antagonists using particle delivery systems. Specifically, aspects of the invention provide pharmaceutical compositions comprising effective amounts of a TRβ agonist or antagonist encapsulated in a particle carrier, as well as methods for using the same to treat various medical diseases and conditions. In various embodiments, the compositions mediate selective TRβ activation in a tissue selective manner.

Absstract of: WO2023000403A1

A Sars-Cov-2 subprotein nano-vaccine, and a preparation method therefor and an application thereof. The nano-vaccine comprises: an organic compound self-assembled from polylactic acid, porphyrin, or a porphyrin derivative, and a Co2+ ion conjugate; Sars-Cov-2 antigen protein; a vaccine adjuvant; and a lipid. The synthetic organic compound has an adjuvant encapsulated in its core and a Sars-Cov-2 antigen protein efficiently loaded on the surface, such that a nano-vaccine system allowing for co-delivery of the Sars-Cov-2 antigen protein and vaccine adjuvant is realized, thereby maximizing the immunogenicity of the Sars-Cov-2 recombinant subprotein and enabling tracking the distribution of the subprotein in an organism by means of fluorescent molecules. In addition, the nano-vaccine is also linked with a polypeptide that can specifically target antigen-presenting cells, so as to promote the uptake of the nano-vaccine by DC cells and promote anti-viral response. The preparation method is simple and efficient and provides a way for effectively preventing Sars-Cov-2 infection.

Absstract of: WO2023003957A1

Nanoconstructs and compositions comprising a nanoparticle coated with an immunoadjuvant (e.g, ATP) and comprising one or more therapeutic agents (e.g, ICD inducer) encapsulated therein; and methods for treating cancer in a subject using such nanoconstructs and compositions, as well as combination immunotherapies.

Absstract of: WO2023003908A1

This disclosure relates to the use of an oxygen-containing liquid as a counter measure against vesicants.

Absstract of: WO2023001317A1

Disclosed in the present invention are an acid-responsive nano-micelle on the basis of the Cherenkov effect, and a preparation method and use therefor. The nano-micelle uses pyropheophorbide a as the photosensitizer main body, and modifies N,N-diisopropylamine, 131I labeled tyrosine or any one of 68Ga, 177Lu, 89Zr labeled tetraazacyclododecane tetraacetic acid, and polyethylene glycol to functionalize, and connects by means of N-Alpha-Fmoc-N-Epsilon-t-Boc-L-Lysine. According to the present invention, a micelle is prepared by a plurality of sequential amide coupling reactions, and can be passively targeted to a tumor site. In normal tissues, due to the aggregation-induced quenching effect, the photodynamics of the micelle is suppressed, and there is no phototoxicity. The micelle can respond to decomposition, recover photodynamically at the tumor site, generate active oxygen species by means of photoexcitation to kill tumors, have Cherenkov self-illumination, can avoid the limited penetration capability of the conventional exogenous light, and finally achieve selective photodynamic therapy of a deep tumor.

Absstract of: WO2023001286A1

Provided are a polyol-modified lipid compound, a preparation method therefor and an application thereof. The lipid compound and lipid nanoparticles prepared therefrom can target and effectively deliver biologically active substances to target cells and sites, and efficiently achieve pharmacological effects of the biologically active substances. In addition, the lipid compound has a singular molecular weight, which is beneficial for controlling differences between batches, improving the stability of finished drugs, and reducing immunogenicity; it is expected to be used for the development and application of related drugs.

Absstract of: WO2023004364A2

Self-assembling nanomaterials and uses thereof in the detection, imaging, and treatment of cancer are described. The self-assembled nanomaterials include a plurality of self-assembling components. Each self-assembling component is amphiphilic, including a hydrophobic self-assembly motif operatively connected to a hydrophilic motif, whereby, upon dissolution in an aqueous solution, the self-assembling components form a micellar structure and generally orient the hydrophilic motifs to remain in contact with the aqueous solution, thereby forming the self-assembled nanomaterial. Self-assembling components can further include a protease cleavable site and/or a functional molecule. The functional molecule can include a dye for detection and/or imaging or a drug for treatment of cancer.

Absstract of: WO2023003826A2

In various embodiments tolerogenic nanoparticles are provided that induce immune tolerance to one or more desired antigen(s) and/or that reduce an immune response to those antigen(s). In certain embodiments the tolerogenic nanoparticle comprises a nanoparticle comprising a biocompatible polymer, a cationic lipid, or a combination thereof; an antigen disposed within or attached to said biocompatible polymer or a nucleic acid encoding said antigen, where said antigen comprises an antigen to which immune tolerance is to be induced by administration of said tolerogenic nanoparticle to a mammal; and a targeting moiety that binds to a scavenger receptor in the liver.

Absstract of: US2023021329A1

The present invention relates to a composition comprising a plurality of silicate nanoparticles; a hydrophilic polymer; and water, and optionally further comprising a thickening polymer; a plurality of zinc oxide particles; a polymer comprising a plurality of quaternary ammonium functional groups; an adhesive polymer; an oil or a polyol. The invention also relates to a use of the composition in prevention and/or treatment of a disease in a mammal, such as skin disease or mastitis. The invention relates further to a sealant of a duct in a body of a mammal comprising said composition.